Li Z, Willke R J, Pinto L A, Rittenhouse B E, Rybak M J, Pleil A M, Crouch C W, Hafkin B, Glick H A
Global Outcomes Research, Pharmacia Corporation, Peapack, New Jersey, USA.
Pharmacotherapy. 2001 Mar;21(3):263-74. doi: 10.1592/phco.21.3.263.34198.
To compare hospital length of stay (LOS), weekly discharges, and days of antibiotic treatment with linezolid (intravenous with oral follow-up) and vancomycin (intravenous only).
Multinational, randomized, phase III trial.
Hospitals in North America, Latin America, and Europe.
Four hundred sixty hospitalized patients with infections of known or suspected methicillin-resistant Staphylococcus species.
Administration of linezolid or vancomycin.
For linezolid recipients, median LOS was 5 and 8 days shorter (p=0.05 and 0.003) in the complicated skin and soft tissue infection intent-to-treat (230 patients) and clinically evaluable (144) samples, and slightly but not significantly shorter in the overall intent-to-treat (460) and clinically evaluable (254) samples. In all samples, linezolid recipients had more discharges in the first week of treatment and fewer days of intravenous therapy than vancomycin recipients.
Our results support linezolid's ability to reduce medical resource use.
比较使用利奈唑胺（静脉给药后口服序贯治疗）和万古霉素（仅静脉给药）时的住院时间（LOS）、每周出院人数以及抗生素治疗天数。
多中心、随机、III期试验。
北美、拉丁美洲和欧洲的医院。
460例已知或疑似耐甲氧西林葡萄球菌感染的住院患者。
给予利奈唑胺或万古霉素。
在复杂皮肤及软组织感染意向性治疗（230例患者）和临床可评估（144例）样本中，接受利奈唑胺治疗的患者中位住院时间分别缩短5天和8天（p = 0.05和0.003），在总体意向性治疗（460例）和临床可评估（254例）样本中，住院时间缩短幅度较小但无统计学意义。在所有样本中，接受利奈唑胺治疗的患者在治疗第一周出院人数多于接受万古霉素治疗的患者，且静脉治疗天数更少。
我们的结果支持利奈唑胺减少医疗资源使用的能力。
